Advanced search
Add to list

Recommendations for the treatment of epilepsies in general practice in Belgium

(2008) Acta Neurologica Belgica. 108(4). p.118-130
Author
Organization
Abstract
The large choice of antiepileptic drugs (AEDs) in Belgium complicates the selection of the appropriate product for the individual patient. International guidelines on the treatment of epilepsy have been published, but are not tailored to the Belgian situation. This publication presents recommendations from a group of Belgian epilepsy experts for the practical management of epilepsy in general practice in Belgium. It includes recommendations for initial monotherapy and add-on treatment in adult patients (>= 16 years) and initial monotherapy in paediatric patients (< 16 years). For these three situations a first choice AED is recommended. One or more alternative first choice AEDs are defined for patients in which certain patient- or AED-related factors preclude the use of the first choice product. Selection of compounds was based on the registration and reimbursement status in Belgium, the level of evidence of efficacy, common daily practice and the personal views and experiences of the authors. The paper reflects the situation in 2008. In addition to the treatment recommendations, other relevant points to consider in the treatment of epilepsy with AEDs are addressed, including comorbidity and age of the patient, the interaction potential, pharmacokinetic properties and safety profile of the AEDs, and generic substitution.
Keywords
LEVETIRACETAM, THERAPEUTICS, EFFICACY, CARBAMAZEPINE, AMERICAN ACADEMY, EPILEPTIC SEIZURES, ANTIEPILEPTIC DRUGS, RANDOMIZED CONTROLLED-TRIAL, TECHNOLOGY-ASSESSMENT SUBCOMMITTEE, QUALITY STANDARDS SUBCOMMITTEE

Citation

Please use this url to cite or link to this publication:

MLA
Boon, Paul, et al. “Recommendations for the Treatment of Epilepsies in General Practice in Belgium.” Acta Neurologica Belgica, vol. 108, no. 4, Acta Medica Belgica, 2008, pp. 118–30.
APA
Boon, P., Engelborghs, S., Hauman, H., Jansen, A., Lagae, L., Legros, B., … van Rijckevorsel, K. (2008). Recommendations for the treatment of epilepsies in general practice in Belgium. Acta Neurologica Belgica, 108(4), 118–130.
Chicago author-date
Boon, Paul, Sebastiaan Engelborghs, Henri Hauman, An Jansen, Lieven Lagae, Benjamin Legros, Michel Ossemann, Bernard Sadzot, Etienne Urbain, and Kenou van Rijckevorsel. 2008. “Recommendations for the Treatment of Epilepsies in General Practice in Belgium.” Acta Neurologica Belgica 108 (4): 118–30.
Chicago author-date (all authors)
Boon, Paul, Sebastiaan Engelborghs, Henri Hauman, An Jansen, Lieven Lagae, Benjamin Legros, Michel Ossemann, Bernard Sadzot, Etienne Urbain, and Kenou van Rijckevorsel. 2008. “Recommendations for the Treatment of Epilepsies in General Practice in Belgium.” Acta Neurologica Belgica 108 (4): 118–130.
Vancouver
1.
Boon P, Engelborghs S, Hauman H, Jansen A, Lagae L, Legros B, et al. Recommendations for the treatment of epilepsies in general practice in Belgium. Acta Neurologica Belgica. 2008;108(4):118–30.
IEEE
[1]
P. Boon et al., “Recommendations for the treatment of epilepsies in general practice in Belgium,” Acta Neurologica Belgica, vol. 108, no. 4, pp. 118–130, 2008.
@article{603121,
  abstract     = {{The large choice of antiepileptic drugs (AEDs) in Belgium complicates the selection of the appropriate product for the individual patient. International guidelines on the treatment of epilepsy have been published, but are not tailored to the Belgian situation. This publication presents recommendations from a group of Belgian epilepsy experts for the practical management of epilepsy in general practice in Belgium. It includes recommendations for initial monotherapy and add-on treatment in adult patients (>= 16 years) and initial monotherapy in paediatric patients (< 16 years). For these three situations a first choice AED is recommended. One or more alternative first choice AEDs are defined for patients in which certain patient- or AED-related factors preclude the use of the first choice product. Selection of compounds was based on the registration and reimbursement status in Belgium, the level of evidence of efficacy, common daily practice and the personal views and experiences of the authors. The paper reflects the situation in 2008.
In addition to the treatment recommendations, other relevant points to consider in the treatment of epilepsy with AEDs are addressed, including comorbidity and age of the patient, the interaction potential, pharmacokinetic properties and safety profile of the AEDs, and generic substitution.}},
  author       = {{Boon, Paul and Engelborghs, Sebastiaan and Hauman, Henri and Jansen, An and Lagae, Lieven and Legros, Benjamin and Ossemann, Michel and Sadzot, Bernard and Urbain, Etienne and van Rijckevorsel, Kenou}},
  issn         = {{0300-9009}},
  journal      = {{Acta Neurologica Belgica}},
  keywords     = {{LEVETIRACETAM,THERAPEUTICS,EFFICACY,CARBAMAZEPINE,AMERICAN ACADEMY,EPILEPTIC SEIZURES,ANTIEPILEPTIC DRUGS,RANDOMIZED CONTROLLED-TRIAL,TECHNOLOGY-ASSESSMENT SUBCOMMITTEE,QUALITY STANDARDS SUBCOMMITTEE}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{118--130}},
  publisher    = {{Acta Medica Belgica}},
  title        = {{Recommendations for the treatment of epilepsies in general practice in Belgium}},
  volume       = {{108}},
  year         = {{2008}},
}

Web of Science
Times cited: